All In Biotech

Drug Trial Radar · NCT06077877

A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Anticancer Activity of GSK4524101 Alone or With Niraparib in Participants With Solid Tumors

A Phase 1/2 First-Time-in-Human, Open-label, Multicenter, Dose Escalation and Expansion Study of the Oral DNA Polymerase Theta Inhibitor (POLQi) GSK4524101 and the PARP Inhibitor (PARPi) Niraparib in Adult Participants With Solid Tumors

Last checked: Nov 20, 2026Latest source record: Apr 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

42

Actual

Start

Oct 24, 2023

Primary completion

Jun 30, 2026

Study completion Jun 30, 2026

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Oct 11, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of this study is to determine the maximum tolerated dose of GSK4524101 monotherapy (MTD) and GSK4524101 in combination with niraparib (MTDc). The study consists of two parts - Part 1 (Dose Escalation) and Part 2 (Dose Expansion).

Conditions

  • Neoplasms

Interventions

  • GSK4524101Drug

    GSK452101 will be administered.

  • NiraparibDrug

    Niraparib will be administered.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1 - Proportion of Participants with Dose Limiting Toxicities (DLTs) during DLT Observation PeriodTime frame: Up to 28 days
  2. Part 1 - Proportion of Participants with Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) based on Severity during DLT Observation PeriodTime frame: Up to 28 days
  3. Part 1 - Duration of Treatment Emergent AEs and SAEs (Days) during DLT Observation PeriodTime frame: Up to 28 days
  4. Part 1 - Percentage of Participants who receive all Planned Doses during DLT Observation PeriodTime frame: Up to 28 days
  5. Part 1 -Percentage of Participants who require dosage interruptions, dose reductions, and drug discontinuations due to adverse reactions during DLT Observation PeriodTime frame: Up to 28 days
  6. Part 2 - Confirmed Objective Response Rate (ORR)Time frame: Up to approximately 52 weeks

Locations

11 sites in 3 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    San Francisco, California

  • GSK Investigational Site

    St Louis, Missouri

  • GSK Investigational Site

    Dallas, Texas

  • GSK Investigational Site

    Houston, Texas

  • GSK Investigational Site

    San Antonio, Texas

  • GSK Investigational Site

    Fairfax, Virginia

  • GSK Investigational Site

    Edmonton, Alberta, Canada

  • GSK Investigational Site

    Toronto, Ontario, Canada

  • GSK Investigational Site

    Montreal, Quebec, Canada

  • GSK Investigational Site

    Panama City, Panama

  • GSK Investigational Site

    Punta Pacifica Panama City Panama, Panama

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.